Perioperative chemotherapy with FLOT regimen in patients with resectable gastric or gastroesophageal junction adenocarcinoma (SIEWERT type I–III). Experience of the N. N. Blokhin russian cancer research center-Reference-Cited by-同舟云学术

Perioperative chemotherapy with FLOT regimen in patients with resectable gastric or gastroesophageal junction adenocarcinoma (SIEWERT type I–III). Experience of the N. N. Blokhin russian cancer research center

Published:2022-12-15 Issue:4 Volume:12 Page:5-13
ISSN:2587-6813
Container-title:Malignant tumours
language:
Short-container-title:Malignant Tumours

Author:

Avdyukhin I. G.¹,Peregorodiev I. N.¹,Kalinin А. Е.¹,Nered S. N.¹,Besova N. S.¹,Tryakin А. А.¹,Artamonova Е. V.¹,Titova Т. А.¹,Obarevich Е. S.¹,Ignatova Е. О.¹,Kozlov N. А.¹,Rossomakhina О. V.²,Shishkina N. А.¹,Kolobanova Е. S.¹,Malikhova О. А.¹,Abgaryan М. G.¹,Nikulin М. P.¹,Arkhiri P. P.¹,Vashakmadze L. А.¹,Hengyan S.³,Suleimanov E. А.⁴,Stilidi I. S.⁵

Affiliation:

1. N. N. Blokhin National Medical Research Center of Oncology

2. St. Luke Lugansk State Medical University

3. Pirogov Russian National Research Medical University

4. Ministry of Health of the Chechen Republic

5. N. N. Blokhin National Medical Research Center of Oncology; Pirogov Russian National Research Medical University

Abstract

To date, gastric cancer patients still have a poor prognosis. Current endoscopic or surgical treatment modalities are radical only for early gastric cancer (T1). Curability dramatically declines as tumor invasion progresses and lymph node metastasеs appear. In Europe and North America, the 5-year overall survival rate of patients with stage T2–4 cancer is 20 % [1]. Combination therapy for gastric cancer is being extensively studied to improve the treatment outcomes [2–6]. Currently, perioperative chemotherapy with FLOT regimen is the mainstay of resectable gastric cancer treatment in Europe. FLOT4-AIO randomized study has shown that the FLOT regimen was associated with significant increase in the median overall survival (50 versus 35 months), disease-free survival (18 versus 30 months) and R0 resection rate compared to ECF / ECХ regimen.In this work we evaluated the efficacy and toxicity of perioperative FLOT regimen in patients with gastric cancer and gastroesophageal junction cancer type I–III cT4aN0M0, cT1–4N + M0, using a prospective database of patients treated at the N. N. Blokhin Russian Cancer Research Center.

Publisher

Russian Society of Clinical Oncology

Subject

General Agricultural and Biological Sciences

Reference13 articles.

1. Reim D, Loos M, Vogl F, et al. Prognostic implications of the seventh edition of the International Union Against Cancer classification for patients with gastric cancer: the Western experience of patients treated in a single-center European institution. J Clin Oncol 2013 ; 31 : 263–71.

2. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006 ; 355 : 11–20.

3. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011 ; 29 : 1715–21.

4. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012 ; 366 : 2074–84.

5. Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Preoperative chemo (radio) therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer 2013 ; 49 : 3149–58.